AURA Aura Biosciences, Inc.
Aura Biosciences, Inc. (AURA) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.31 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.9% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Aura Biosciences, Inc.
Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company's lead product candidate includes AU-011. Aura Biosciences Inc. is based in CAMBRIDGE, Mass.
Sector
Healthcare
Industry
Biotechnology